This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wei, M. Articles by Olopade, O. I. Search for Related Content PubMed PubMed Citation Articles by Wei, M. Articles by Olopade, O. I.

BRCA1 Promoter Methylation in Sporadic Breast Cancer Is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy

¹ Center for Clinical Cancer Genetics, Department of Medicine and Departments of ² Health Studies, ³ Pathology, and ⁴ Human Genetics, University of Chicago, Chicago, Illinois

Requests for reprints: Olufunmilayo I. Olopade, Center for Clinical Cancer Genetics, Department of Medicine, University of Chicago, Chicago, IL 60637-1463. Phone: 773-702-1632; Fax: 773-702-0963; E-mail: folopade{at}medicine.bsd.uchicago.edu.

To explore the molecular mechanisms for the similarities between inherited and noninherited forms of breast cancer, we tested the hypothesis that inactivation of BRCA1 by promoter hypermethylation is associated with reduced gene copy number and chromosome 17 aneusomy as observed in tumors from BRCA1 mutation carriers. Using a combination of methylation-specific PCR analysis and fluorescence in situ hybridization, we observed varying degrees of promoter methylation in 39 of 131 (29.8%) primary tumors. Despite significant tumor heterogeneity, mean copy numbers of BRCA1 and CEP17 per cell were lower in methylated cases compared with unmethylated cases [1.78 versus 2.30 (P = 0.001) and 1.85 versus 2.29 (P = 0.005), respectively]. Methylation was more frequently observed in younger women (P = 0.05) with high-grade (P = 0.001), estrogen receptor–negative (P = 0.04), and progesterone receptor–negative (P = 0.01) tumors. Moreover, methylation was associated with reduced or absent BRCA1 transcripts, which was reversible in the heavily BRCA1-methylated cell line UACC3199 following treatment with 5-aza-2'-deoxycytidine and trichostatin A. We identified five CpGs at positions –533, –355, –173, –21, and +44 as critical in the reexpression of BRCA1. We conclude that BRCA1 methylation contributes to a subset of sporadic breast cancers with the resulting molecular and clinicopathologic phenotype similar to that of hereditary BRCA1-associated breast cancers. Our data support a model of carcinogenesis in which BRCA1 promoter methylation may serve as a "first hit," much like an inherited germ line mutation, and promote tumor progression down a restricted set of molecular pathways.

This article has been cited by other articles:

				L. J Suva, R. J Griffin, and I. Makhoul Mechanisms of bone metastases of breast cancer Endocr. Relat. Cancer, September 1, 2009; 16(3): 703 - 713. [Abstract] [Full Text] [PDF]

				H. N. Horne, P. S. Lee, S. K. Murphy, M. A. Alonso, J. A. Olson Jr., and J. R. Marks Inactivation of the MAL Gene in Breast Cancer Is a Common Event That Predicts Benefit from Adjuvant Chemotherapy Mol. Cancer Res., February 1, 2009; 7(2): 199 - 209. [Abstract] [Full Text] [PDF]

				O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo Advances in Breast Cancer: Pathways to Personalized Medicine Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999. [Abstract] [Full Text] [PDF]

				D S P Tan, C Marchio, and J S Reis-Filho Hereditary breast cancer: from molecular pathology to tailored therapies J. Clin. Pathol., October 1, 2008; 61(10): 1073 - 1082. [Abstract] [Full Text] [PDF]

				H. T. Lynch, J. N. Marcus, and W. S. Rubinstein Stemming the Tide of Cancer for BRCA1/2 Mutation Carriers J. Clin. Oncol., September 10, 2008; 26(26): 4239 - 4243. [Full Text] [PDF]

				S. M. Tan-Wong, J. D. French, N. J. Proudfoot, and M. A. Brown Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene PNAS, April 1, 2008; 105(13): 5160 - 5165. [Abstract] [Full Text] [PDF]

				Y. Ma, C. Hu, A. T. Riegel, S. Fan, and E. M. Rosen Growth Factor Signaling Pathways Modulate BRCA1 Repression of Estrogen Receptor-{alpha} Activity Mol. Endocrinol., August 1, 2007; 21(8): 1905 - 1923. [Abstract] [Full Text] [PDF]

				M. J. Fackler, K. Malone, Z. Zhang, E. Schilling, E. Garrett-Mayer, T. Swift-Scanlan, J. Lange, R. Nayar, N. E. Davidson, S. A. Khan, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin. Cancer Res., June 1, 2006; 12(11): 3306 - 3310. [Abstract] [Full Text] [PDF]